Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:anticoagulant
factor Xa inhibitor |
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2011 |
| gptkbp:ATCCode |
B01AF03
|
| gptkbp:bioavailability |
62%
|
| gptkbp:brand |
gptkb:Lixiana
gptkb:Savaysa |
| gptkbp:CASNumber |
480449-70-5
|
| gptkbp:chemicalClass |
pyridine derivative
|
| gptkbp:contraindication |
active pathological bleeding
severe hepatic impairment |
| gptkbp:developedBy |
gptkb:Daiichi_Sankyo
|
| gptkbp:eliminationHalfLife |
10-14 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:hasMolecularFormula |
C24H30ClN7O4S
|
| https://www.w3.org/2000/01/rdf-schema#label |
edoxaban
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits factor Xa
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:proteinBinding |
55%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:anemia
bleeding rash |
| gptkbp:usedFor |
prevention of stroke in atrial fibrillation
treatment of deep vein thrombosis treatment of pulmonary embolism |
| gptkbp:bfsParent |
gptkb:CYP3A4
|
| gptkbp:bfsLayer |
5
|